The preclinical stage company will use the funds to further development of their novel nanoparticle drug delivery platform and advance industry partnerships.
All of the company’s original investors participated in this second seed round. CEO Gerald Rea said, “This is a clear sign of confidence in our drug delivery platform technology and the commercial potential. Our strong preclinical data, growing world-class team, and industry interest give our company and investors great confidence going forward.”
Toralgen’s poly-bile nanoparticle platform is unique in that it eliminates the challenges of oral drug delivery in one, simple-to-fabricate nanopill. These nanopills also localize delivery of drug agents and potentially improve efficacy and safety of a wide range of therapies. Toralgen currently has two candidates in preclinical testing for the oral delivery of diabetes agents.
About Toralgen, Inc.
Toralgen, Inc. is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics. Its poly-bile nanoparticle platform eliminates many of the inherent challenges of biologics and has the potential to improve outcomes through optimized drug delivery. Toralgen is currently studying treatments for diabetes and autoimmune disorders. For information or to inquire about possible collaborations, visit our website.
Contact: Dave Moore, Toralgen, firstname.lastname@example.org